Patents Assigned to Hoffmann-La Roche
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE
    Publication number: 20180344848
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD79b antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD79b antibody-drug conjugate.
    Type: Application
    Filed: August 10, 2018
    Publication date: December 6, 2018
    Applicants: Hoffmann-La Roche Inc., Genentech, Inc.
    Inventors: Christian Klein, Sabine Lang, Pablo Umana, Andrew Polson
  • NOVEL BISPECIFIC ANTIGEN BINDING MOLECULES CAPABLE OF SPECIFIC BINDING TO CD40 AND TO FAP
    Publication number: 20180340030
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: April 3, 2018
    Publication date: November 29, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Alexander BUJOTZEK, Harald DUERR, Guy GEORGES, Christian KLEIN, Stephane LECLAIR, Moritz RAPP, Eva Carina SUM, Christine TRUMPFHELLER, Pablo UMAÑA
  • PYRAZOL-PYRIDINE DERIVATIVES
    Publication number: 20180339975
    Abstract: The present invention relates to compounds of formula I wherein R1? is CH3; R1 is CH3, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1? and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, CH3, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopropyl-methyl or hydroxy-methyl; R3 is hydrogen, Cl, F, CF3, CH3, isopropyl, methoxy, cyano or cyclopropyl; R4 is hydrogen, CH3, F or Cl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.
    Type: Application
    Filed: July 30, 2018
    Publication date: November 29, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marius HOENER, Juergen WICHMANN
  • Method for differentiation of pluripotent stem cells into multi-competent renal precursors
    Patent number: 10138468
    Abstract: This application relates to a method for differentiating pluripotent stem cells (PSCs) into multi-competent renal precursor cells expressing Six2. These renal precursor cells are able to differentiate into fully functional and fully differentiated podocytes. Moreover this application relates to a method for differentiating human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) into defined renal precursor cells expressing Six2 and podocytes based on linked steps of chemically defined medium inductions.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: November 27, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jacques Bailly, Osele Ciampi, Martin Graf, Roberto Iacone, Christoph Patsch
  • Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
    Patent number: 10137170
    Abstract: Herein is reported a fusion polypeptide comprising i) one, two, three or four incretin receptor ligand polypeptides, and ii) one human immunoglobulin Fc-region, wherein at least one of the incretin receptor ligand polypeptides comprises an amino acid that is covalently conjugated to a lipid, and wherein each of the one, two, three or four incretin receptor ligand polypeptides is covalently conjugated by a peptide bond to a terminus of the human immunoglobulin Fc-region, whereby to each terminus of the human immunoglobulin Fc-region only a single incretin receptor ligand polypeptide is conjugated.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: November 27, 2018
    Assignees: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, HOFFMANN-LA ROCHE INC.
    Inventors: Sara Belli, Konrad Bleicher, Richard D. Dimarchi, Eike Hoffmann, Eric A. Kitas, Anish A. Konkar
  • 2-phenyl or 2-hetaryl imidazol[1,2-a]pyridine derivatives
    Patent number: 10138234
    Abstract: The invention relates to compounds of formula I: and to pharmaceutically acceptable acid addition salts thereof, wherein R1-R6, Ra, and Rb have any of the values defined in the specification. The compounds are suitable as imaging tools.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: November 27, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Edilio Borroni, Luca Gobbi, Michael Honer, Henner Knust, Matthias Koerner, Dieter Muri
  • Bivalent, bispecific antibodies
    Patent number: 10138293
    Abstract: The present invention relates to nucleic acids which encode the heavy chains and light chains of a novel domain exchanged, bivalent, bispecific antibody, and vectors comprising the same.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: November 27, 2018
    Assignee: HOFFMANN-LA ROCHE, INC.
    Inventors: Christian Klein, Wolfgang Schaefer
  • PRODUCTION OF THIOESTERS USING SORTASE
    Publication number: 20180334661
    Abstract: Herein is reported a method for the enzymatic production of a thioester comprising incubating i) a first polypeptide comprising the amino acid sequence LPXTG (SEQ ID NO: 01, wherein X can be any amino acid residue), ii) a second polypeptide that has at its N-terminus a cysteine amino acid residue or is a cysteinyl compound, and iii) a third polypeptide with sortase A activity.
    Type: Application
    Filed: March 23, 2018
    Publication date: November 22, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Martin Schatte, Mara Boenitz-Dulat, Frank Bergmann
  • NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES
    Publication number: 20180334461
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Application
    Filed: December 19, 2017
    Publication date: November 22, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Taishan Hu, Xingchun Han, Buyu Kou, Hong Shen, Shixiang Yan, Zhisen Zhang
  • NOVEL PYRIDINE DERIVATIVES
    Publication number: 20180327360
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: July 20, 2018
    Publication date: November 15, 2018
    Applicants: Hoffmann-La Roche Inc., Eidgenossische Technische Hochschule Zurich
    Inventors: Luca Gobbi, Uwe Grether, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Roger Slavik
  • Immunoconjugates
    Publication number: 20180326010
    Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: April 2, 2018
    Publication date: November 15, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Valeria G. Nicolini, Stefan Seeber, Pablo Umana, Inja Waldhauer
  • METHOD FOR THE DETECTION OF A BINDING PARTNER OF A MULTISPECIFIC BINDER
    Publication number: 20180328942
    Abstract: Herein is reported a method for the detection of free antigen of a multispecific antibody in a sample, whereby the antigen to be detected can be specifically bound by a first binding site of the multispecific antibody, comprising the step of incubating a sample comprising free antigen and multispecific antibody with an anti-idiotypic antibody, which specifically binds to a second binding specificity of the bispecific antibody, which is different from the first binding specificity, whereby the anti-idiotypic antibody is bound to a solid phase.
    Type: Application
    Filed: March 16, 2018
    Publication date: November 15, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Kay-Gunnar STUBENRAUCH, Uwe WESSELS
  • BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3
    Publication number: 20180326054
    Abstract: The invention relates to bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: April 3, 2018
    Publication date: November 15, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Jens Fischer, Sabine Imhof-Jung, Christian Klein, Stefan Seeber, Patrick Alexander Aaron Weber
  • CELLULAR BASED FRET ASSAY FOR THE DETERMINATION OF SIMULTANEOUS BINDING
    Publication number: 20180328920
    Abstract: Herein is reported a method for the determination of the simultaneous binding of a bispecific antibody to a first and a second antigen comprising the steps of a) incubating a cell expressing cell-membrane bound FRET-donor-tagged first antigen and FRET-acceptor-tagged second antigen with the bispecific antibody, and b) determining the simultaneous binding of the bispecific antibody by determining the energy transfer from the FRET-donor to the FRET-acceptor.
    Type: Application
    Filed: March 30, 2018
    Publication date: November 15, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan SEEBER, Jens FISCHER, Georg FERTIG
  • NOVEL PYRIDINE DERIVATIVES
    Publication number: 20180327396
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: July 24, 2018
    Publication date: November 15, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Luca Gobbi, Uwe Grether, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans
  • Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection
    Publication number: 20180327425
    Abstract: The present invention relates to novel compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: March 30, 2018
    Publication date: November 15, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Yimin Hu, Chengang Zhou, Mingwei Zhou, Houguang Shi, Yongqiang Liu, Hong Shen, Maarten Vercruysse, Shixiang Yan, Xuefei Tan, Xianfeng Lin, Fabian Dey
  • Immunoconjugates
    Publication number: 20180326011
    Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and a bispecific antigen binding molecule that binds to PD-1 and Tim-3. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: April 2, 2018
    Publication date: November 15, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Stefan Seeber, Pablo Umana, Inja Waldhauer
  • DIAZACARBAZOLE DERIVATIVES AS TAU-PET-LIGANDS
    Publication number: 20180326099
    Abstract: The present invention relates to compounds that may be used for binding and imaging tau aggregates and related beta-sheet aggregates including, besides others, beta-amyloid aggregates or alpha-synuclein aggregates.
    Type: Application
    Filed: May 15, 2018
    Publication date: November 15, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Luca GOBBI, Henner KNUST, Matthias KOERNER, Dieter MURI
  • ANTIGEN BINDING PROTEINS
    Publication number: 20180312573
    Abstract: The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.
    Type: Application
    Filed: April 24, 2018
    Publication date: November 1, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Birgit BOSSENMAIER, Hubert KETTENBERGER, Christian KLEIN, Klaus-Peter KUENKELE, Joerg-Thomas REGULA, Wolfgang SCHAEFER, Manfred SCHWAIGER, Claudio SUSTMANN
  • NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS
    Publication number: 20180312515
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: March 23, 2018
    Publication date: November 1, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Patrizio Mattei, Jerome Hert, Daniel Hunziker, Markus Rudolph, Petra Schmitz, Patrick Di Giorgio